← Back to Search

ZD 1839 + Chemotherapy for Lung Cancer

Phase 3

Waitlist Available

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically proven non-small cell lung cancer Stage III disease that is not curable with surgery or radiotherapy OR Stage IV disease chemotherapy naive

Renal: Creatinine less than 1.5 times ULN, Creatinine clearance greater than 60 mL/min

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying giving chemotherapy with or without ZD 1839 to see if it is more effective in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Who is the study for?

This trial is for adults with stage IIIB or IV non-small cell lung cancer who haven't had chemotherapy. They must be relatively healthy, with good blood counts and no severe heart, liver, or lung disease. People taking certain drugs that affect the body's enzyme systems or hormone therapies known to impact lung cancer can't join.Check my eligibility

What is being tested?

The study is testing whether adding ZD 1839 to standard combination chemotherapy improves outcomes in patients with advanced non-small cell lung cancer. Participants are randomly assigned to receive either just chemo or chemo plus ZD 1839.See study design

What are the potential side effects?

ZD 1839 may cause skin reactions, diarrhea, and abnormal liver function tests. Chemotherapy can lead to hair loss, nausea, fatigue, increased risk of infection due to low blood counts, and other organ-related side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer is at an advanced stage and hasn't been treated with chemotherapy.

Select...

My kidney function tests are within normal limits.

Select...

My heart condition is stable and under control.

Select...

I am 18 years old or older.

Select...

I can take care of myself and perform daily activities.

Select...

My liver function tests are within the required range.

Select...

My lung condition is stable and not severe.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor

4,267 Previous Clinical Trials

288,611,981 Total Patients Enrolled

Ron StaugarrdStudy ChairAstraZeneca

1 Previous Clinical Trials

Media Library

Combination Chemotherapy Clinical Trial Eligibility Overview. Trial Name: NCT00006048 — Phase 3

Lung Cancer Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00006048 — Phase 3

Combination Chemotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006048 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people still able to sign up for this research project?

"Although this trial is not seeking patients at the moment, that doesn't mean it won't in the future. This study was initially posted on 5/1/2000 and was last edited on 12/18/2013. Right now, there are 2098 other trials actively recruiting patients."

Answered by AI